ArticleNucleic acids research2025
METTL3 and METTL14 determine human neural fate specifications.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Morpholino Knockdown in Zebrafish: A Tool to Investigate the Functional Impact of Variants of Unknown Significance in Mitochondrial Diseases.Neuromolecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
METTL3/METTL14, the canonical methyltransferase complex modifying N6-methyladenosine (m6A) on mRNAs, plays critical roles in development and various diseases. However, its precise functions in specifying neural fate from human embryonic stem cells (hESCs) remain poorly understood. Here, we demonstrate, using an inducible knockout system, that METTL3/METTL14 deletion impairs the generation of neural progenitor cells (NPCs) from hESCs. Furthermore, inducible METTL3/METTL14-deficient NPCs exhibit compromised long-term proliferation and fail to differentiate into neurons. Mechanistically, METTL3 is enriched in gene loci essential for neurogenesis and chromatin remodeling in human NPCs, thereby promoting chromatin accessibility at these sites. Importantly, forced expression of BRM, a catalytic component of the chromatin-remodeling BAF complex, in METTL3-deficient hESCs rescues the defects in neural fate specifications caused by METTL3 loss. Our study systematically defines the essential requirement of METTL3 and METTL14 in ensuring the fidelity and neuronal specification of human NPCs, and underscores the coordination among distinct epigenetic regulators in neural development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.